towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
MATERIALS & METHODS<br />
TRAIL‐induced migration and invasion<br />
Cell lines and chemicals<br />
NSCLC cells, H460, H322, SW1573, and A549, derived from ATCC in 2003, were cultured<br />
as monolayers in RPMI 1640 medium, supplemented with 10% (v/v) FBS, 100 units/ml<br />
penicillin, and 100 µg/ml streptomycin. Cells were maintained in a humidified 5% CO2<br />
atmosphere at 37°C. The cell lines were tested <strong>for</strong> their authenticity by short tandem<br />
repeats (STR) profiling DNA fingerprinting (Baseclear, Leiden, The Netherlands). PP2,<br />
PD098059 (Sigma‐Aldrich, St. Louis, MO, USA), dasatinib and saracatinib (both from LC<br />
Laboratories, Woburn, MA, USA) were dissolved in DMSO to 20 mM stock solutions.<br />
LY294002 (Sigma‐Aldrich) was dissolved in DMSO to 10 mM stock solution.<br />
MTT assay<br />
A total of 10,000 cells were seeded in 96‐well plates (Greiner Bio‐One, Frickenhausen,<br />
Germany). The next day 100 µl medium with or without TRAIL was added with increasing<br />
concentrations to the cells. After 24 h incubation, the medium was discarded and 50 µl of<br />
a MTT solution (0.5 mg/ml (Sigma‐Aldrich) in HBSS) was added and incubated at 37°C <strong>for</strong><br />
1.5 h. The <strong>for</strong>mazan crystals were dissolved using 150 µl dimethyl sulfoxide (DMSO) and<br />
absorbance was measured at 540 nm (Tecan, Männedorf, Switzerland). Results are<br />
presented as percentage of viable cells taking the control (untreated cells) as 100%<br />
survival. The concentration resulting in 50% of cell growth inhibition (IC50) was derived<br />
from the growth inhibition curve.<br />
Receptor cell surface expression<br />
Analysis of TRAIL‐<strong>receptor</strong> membrane expression was per<strong>for</strong>med using a flow cytometer<br />
(Epics Elite, Coulter‐Electronics, Hialeah, FL, USA). Adherent cells were harvested by<br />
treatment with trypsin and washed twice in PBS containing 1% BSA. Appropriate<br />
concentrations of antibodies dissolved in PBS/1% BSA were added to the cells. The<br />
following antibodies were used to determine TRAIL <strong>receptor</strong> membrane expression:<br />
TRAIL‐R1 (HS101), TRAIL‐R2 (HS201), TRAIL‐R3 (HS301), TRAIL‐R4 (HS402), all from Alexis.<br />
Mouse IgG (DAKO) was used as isotype control. Subsequently, cells were incubated <strong>for</strong><br />
30 min on ice, washed twice with cold PBS/1% BSA, and incubated with FITC‐conjugated<br />
rabbit‐antimouse (DAKO, Glostrup, Denmark) <strong>for</strong> 30 min on ice. After washing, the cells<br />
were analyzed by flow cytometry. Surface expression is shown as a ratio of the signal of<br />
the specific TRAIL‐<strong>receptor</strong> antibody and the negative isotype control antibody.<br />
Migration assays<br />
Cell migration was determined using the wound healing assay as described previously<br />
[13]. In brief, NSCLC cells were seeded in 96‐wells plates and grown till confluence. A 96<br />
well floating‐pin transfer device with a pin diameter of 1.58 mm coming to a flat point at<br />
‐ 63 ‐